Summary

Apixaban, an oral factor Xa inhibitor, is noninferior to enoxaparin plus warfarin for the treatment of acute symptomatic proximal deep vein thrombosis and pulmonary embolism, and is associated with significantly less bleeding compared with conventional therapy. Administered in fixed doses, apixaban may simplify the treatment of acute venous thromboembolism. This article presents the results of the Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism [AMPLIFY; NCT00643201].